Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase I/II Study for Relapsed or Refractory CD19+ B-acute Lymphoblastic Leukemia

NCT03155191 is registered in ClinicalTrials.gov with Takara Bio Inc. as lead sponsor.

NCT NCT03155191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03155191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase I/II Study for Relapsed or Refractory CD19+ B-acute Lymphoblastic Leukemia
Lead sponsor
Takara Bio Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 1, 2017
Completion date
March 31, 2035
Enrollment
21 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoblastic leukemia, acute adult